Valuation: Lite Strategy, Inc.

Market Cap 23.75M 21.66M 20.03M 18.08M 34.04M 2.22B 35.38M 242M 95.62M 1.2B 89.11M 87.24M 3.78B P/E 2025
-1.03x
P/E 2026 -0.45x
Enterprise Value 18.05M 16.46M 15.22M 13.73M 25.86M 1.69B 26.88M 184M 72.65M 910M 67.7M 66.28M 2.87B EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
80.73%
Yield 2025 *
-
Yield 2026 -
1 day+1.56%
1 week-18.06%
Current month-27.93%
1 month-29.81%
3 months-8.48%
6 months-26.28%
Current year-38.85%
1 week 0.76
Extreme 0.75705
0.93
1 month 0.76
Extreme 0.75705
1.27
Current year 0.69
Extreme 0.6888
1.65
1 year 0.69
Extreme 0.6888
1.99
3 years 0.69
Extreme 0.6888
9
5 years 0.69
Extreme 0.6888
71
10 years 0.69
Extreme 0.6888
102.8
Manager TitleAgeSince
Chief Executive Officer 56 01/08/2024
Director TitleAgeSince
Director/Board Member 57 11/06/2013
Chairman 75 01/08/2024
Director/Board Member 56 14/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
10/22/26 A Free

Director

100,000 0.3289%
10/22/26 A Free

Chief Executive Officer

600,000 1.9732%
10/22/26 A Free

Director

100,000 0.3289%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%-18.06%-58.18%-86.59% 23.75M
-1.34%-3.09%+56.10%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.01% 58.86B
+0.54%+0.45%+25.96%+87.77% 55.22B
-2.34%-3.90%+10.90%+115.97% 47.21B
+0.09%-6.08%+18.67%+25.90% 42.45B
-2.58%+0.24%+18.54%+41.28% 36.44B
-1.76%-11.56%+126.44%+649.27% 35.19B
-0.17%-1.83%+82.46%+57.69% 32.66B
-1.69%-0.79%-40.58%+382.68% 26.73B
Average -0.71%-3.66%+24.93%+143.28% 40B
Weighted average by Cap. -0.84%-2.92%+34.21%+143.96%

Financials

2025 2026
Net sales - -
Net income -15.94M -14.54M -13.45M -12.13M -22.85M -1.49B -23.75M -162M -64.19M -804M -59.82M -58.57M -2.54B -71.15M -64.89M -60M -54.14M -102M -6.65B -106M -725M -286M -3.59B -267M -261M -11.33B
Net Debt -18.01M -16.43M -15.19M -13.71M -25.81M -1.68B -26.83M -183M -72.51M -908M -67.57M -66.15M -2.87B -5.71M -5.2M -4.81M -4.34M -8.18M -533M -8.5M -58.11M -22.97M -288M -21.41M -20.96M -909M
Projected Income Statement - Annual - Lite Strategy, Inc.
Logo Lite Strategy, Inc.
Lite Strategy, Inc. is a pharmaceutical company focused on developed and differentiated cancer therapies. The Company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral, once-daily, selective PI3Kd inhibitor. CDK9 functions in cell cycle regulation, and its modulation in cancer and autoimmune diseases. It is a transcriptional regulator of the myeloid leukemia cell differentiation protein (Mcl-1). Zandelisib is an oral, once-daily, selective PI3Kd inhibitor that is developed for the treatment of indolent B-cell lymphomas. Its approach to pre-clinical drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address medical needs. It holds Litecoin (LTC) tokens as a primary asset as part of an institutional treasury. LTC is an open source, global payment network that is decentralized without any central authorities.
Employees
5
Date Price Change Volume
18/11/26 $0.8072 +1.56% 148,448
17/11/26 $0.7948 -7.20% 267,992
16/11/26 $0.8565 +1.16% 434,604
13/11/26 $0.8467 -6.64% 435,399
12/11/26 $0.9069 -7.94% 258,199

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Lite Strategy, Inc.
  1. Stock Market
  2. Stocks
  3. LITS Stock